JPWO2020106927A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106927A5 JPWO2020106927A5 JP2021529111A JP2021529111A JPWO2020106927A5 JP WO2020106927 A5 JPWO2020106927 A5 JP WO2020106927A5 JP 2021529111 A JP2021529111 A JP 2021529111A JP 2021529111 A JP2021529111 A JP 2021529111A JP WO2020106927 A5 JPWO2020106927 A5 JP WO2020106927A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- gaboxadol
- acceptable salt
- administration
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950004346 Gaboxadol Drugs 0.000 claims description 36
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 206010010144 Completed suicide Diseases 0.000 claims description 13
- 206010054089 Depressive symptom Diseases 0.000 claims description 13
- 230000002142 suicide Effects 0.000 claims description 13
- -1 SAGE-217 Chemical compound 0.000 claims description 9
- 206010042458 Suicidal ideation Diseases 0.000 claims description 8
- 230000002195 synergetic Effects 0.000 claims description 8
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 6
- 229960003299 ketamine Drugs 0.000 claims description 6
- 230000001225 therapeutic Effects 0.000 claims description 5
- 230000036868 Blood Concentration Effects 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- AURFZBICLPNKBZ-YZRLXODZSA-N Pregnanolone Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 claims description 4
- 230000001154 acute Effects 0.000 claims description 4
- 229960003692 aminobutyric acid Drugs 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- DMJHZVARRXJSEG-UHFFFAOYSA-N Decoglurant Chemical compound C1=NC(N)=CC=C1C#CC1=C2N=C(C=3C=CC(=CC=3)C(F)(F)F)C=C(C(F)(F)F)N2N=C1 DMJHZVARRXJSEG-UHFFFAOYSA-N 0.000 claims description 3
- DVBUEXCIEIAXPM-PJUQSVSOSA-N (2R)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@@](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)(CC=2C=CC=CC=2)CCC1 DVBUEXCIEIAXPM-PJUQSVSOSA-N 0.000 claims description 2
- JWMFYGXQPXQEEM-WZBAXQLOSA-N (8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 claims description 2
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 claims description 2
- 230000035533 AUC Effects 0.000 claims description 2
- RECBFDWSXWAXHY-IAGOWNOFSA-N CERC-301 Chemical compound C1=CC(C)=CC=C1COC(=O)N1C[C@@H](F)[C@@H](CNC=2N=CC=CN=2)CC1 RECBFDWSXWAXHY-IAGOWNOFSA-N 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N Dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 claims description 2
- 229950004794 Dizocilpine Drugs 0.000 claims description 2
- 229950006567 GANAXOLONE Drugs 0.000 claims description 2
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 claims description 2
- USPYDUPOCUYHQL-VEVMSBRDSA-N Hydroxydione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 USPYDUPOCUYHQL-VEVMSBRDSA-N 0.000 claims description 2
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N Lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 claims description 2
- LFAGGDAZZKUVKO-JAGWWQSPSA-N MGS-0039 Chemical compound O([C@@H]1C[C@@H]2[C@@H]([C@@]2(F)C(O)=O)[C@]1(N)C(O)=O)CC1=CC=C(Cl)C(Cl)=C1 LFAGGDAZZKUVKO-JAGWWQSPSA-N 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- NCGLTZSBTFVVAW-KNXRZYMVSA-N Minaxolone Chemical compound C1[C@@H](N(C)C)[C@@H]2[C@@]3(C)C[C@H](OCC)[C@@H](O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C NCGLTZSBTFVVAW-KNXRZYMVSA-N 0.000 claims description 2
- 210000002381 Plasma Anatomy 0.000 claims description 2
- GIBQQARAXHVEGD-BSOLPCOYSA-N Rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims description 2
- 206010065604 Suicidal behaviour Diseases 0.000 claims description 2
- 206010042464 Suicide attempt Diseases 0.000 claims description 2
- 230000037098 T max Effects 0.000 claims description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N Tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 2
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims description 2
- 230000001430 anti-depressive Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229950003508 apimostinel Drugs 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- 229950008597 drug INN Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229950007402 eltanolone Drugs 0.000 claims description 2
- 238000002582 magnetoencephalography Methods 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- 229960004798 minaxolone Drugs 0.000 claims description 2
- 230000001525 neurosteroidal Effects 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 230000000306 recurrent Effects 0.000 claims description 2
- 229960001918 tiagabine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 239000004480 active ingredient Substances 0.000 claims 2
- 229950005807 Decoglurant Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- SCOOTUMXCXKEAD-UHFFFAOYSA-N ethyl N-[2-amino-4-[(2,4,6-trimethylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=C(C)C=C1C SCOOTUMXCXKEAD-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XWYBFXIUISNTQG-VKMGZQQJSA-N Alfadolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 XWYBFXIUISNTQG-VKMGZQQJSA-N 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770287P | 2018-11-21 | 2018-11-21 | |
| US62/770,287 | 2018-11-21 | ||
| PCT/US2019/062554 WO2020106927A1 (en) | 2018-11-21 | 2019-11-21 | Gaboxadol for reducing risk of suicide and rapid relief of depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514194A JP2022514194A (ja) | 2022-02-10 |
| JPWO2020106927A5 true JPWO2020106927A5 (ko) | 2022-11-18 |
Family
ID=70728606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529111A Pending JP2022514194A (ja) | 2018-11-21 | 2019-11-21 | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220008398A1 (ko) |
| EP (1) | EP3883566A4 (ko) |
| JP (1) | JP2022514194A (ko) |
| KR (1) | KR20210110585A (ko) |
| CN (1) | CN113395962A (ko) |
| AU (1) | AU2019384157A1 (ko) |
| BR (1) | BR112021009944A2 (ko) |
| CA (1) | CA3120856A1 (ko) |
| GB (1) | GB2594616A (ko) |
| IL (1) | IL283311A (ko) |
| MX (1) | MX2021005992A (ko) |
| SG (1) | SG11202105358RA (ko) |
| WO (1) | WO2020106927A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| EP3883566A4 (en) * | 2018-11-21 | 2022-09-07 | Certego Therapeutics Inc. | GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF |
| CA3182508A1 (en) | 2020-05-20 | 2021-11-25 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| TW200509918A (en) | 2003-06-25 | 2005-03-16 | Lundbeck & Co As H | Treatment of depression and other affective disorders |
| US20050234093A1 (en) | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| TW200501951A (en) | 2003-06-25 | 2005-01-16 | Lundbeck & Co As H | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
| ES2341004T3 (es) | 2003-06-25 | 2010-06-14 | H. Lundbeck A/S | Gaboxadol para tratar la depresion y otros trastornos afectivos. |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| US20050137222A1 (en) | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| CN1942185A (zh) | 2004-04-02 | 2007-04-04 | H.隆德贝克有限公司 | 用加波沙朵治疗呼吸功能损伤 |
| EP1734956A1 (en) | 2004-04-02 | 2006-12-27 | H.Lundbeck A/S | Treatment of impaired respiratory function with gaboxadol |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| US8022084B2 (en) | 2005-01-28 | 2011-09-20 | H. Lundbeck A/S | Polymorphic forms of a GABAA agonist |
| EP1906953A4 (en) | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
| DE102005020882A1 (de) | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20080159958A1 (en) * | 2006-12-27 | 2008-07-03 | Abbott Laboratories | Determination of histamine-3 bioactivity |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| GB0810063D0 (en) | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| JP2012501301A (ja) | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物 |
| US11083732B2 (en) * | 2014-03-31 | 2021-08-10 | University Of Maryland, Baltimore | Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants |
| WO2015171547A1 (en) | 2014-05-05 | 2015-11-12 | Ovid Therapeutics Inc. | Methods of treating cognitive impairment associated with neurodegenerative disorders |
| HUE055155T2 (hu) | 2014-06-06 | 2021-11-29 | Ovid Therapeutics Inc | Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére |
| WO2016057533A1 (en) | 2014-10-06 | 2016-04-14 | Ghaemi Seyyed Nassir | Primary and secondary prevention of dementias and suicide with trace dose lithium |
| CA2977437C (en) | 2015-03-24 | 2023-07-04 | H. Lundbeck A/S | Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol |
| US20160317477A1 (en) | 2015-04-30 | 2016-11-03 | Ovid Therapeutics Inc. | Methods of treating prader-willi syndrome |
| AR105378A1 (es) | 2015-07-17 | 2017-09-27 | Ovid Therapeutics Inc | Métodos de tratamiento de trastornos del desarrollo con gaboxadol |
| US9682069B2 (en) * | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| KR20180031721A (ko) | 2015-07-17 | 2018-03-28 | 오비드 테라퓨틱스 인크. | 가복사돌로 발달장애들을 치료하는 방법들 |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| AR105670A1 (es) | 2015-08-11 | 2017-10-25 | Ovid Therapeutics Inc | Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| KR20180048707A (ko) | 2015-08-11 | 2018-05-10 | 오비드 테라퓨틱스 인크. | 중환자 치료 동안 사용을 위한 진정제 및 비경구 제제의 방법들 |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| US20170119704A1 (en) | 2015-10-13 | 2017-05-04 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
| MX2018013973A (es) | 2016-05-26 | 2019-03-28 | Ovid Therapeutics Inc | Metodos de tratamiento de sindromes de comportamiento usando pipradrol. |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| EP3528807A4 (en) | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
| US10737984B2 (en) | 2016-11-30 | 2020-08-11 | Hrl Laboratories, Llc | Formulations and methods for 3D printing of ceramic matrix composites |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20190060400A1 (en) | 2017-03-15 | 2019-02-28 | Ovid Therapeutics Inc. | Use of designer receptors exclusively activated by designer drugs and ultrasound in the treatment of seizure disorders |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| WO2018222957A1 (en) | 2017-06-01 | 2018-12-06 | Ovid Therapeutics Inc. | Treatment of developmental disorders with imidazolone derivatives |
| US20190000993A1 (en) | 2017-06-28 | 2019-01-03 | Ovid Therapeutics Inc. | Treatment of developmental syndromes |
| WO2019028234A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
| AU2018320849A1 (en) | 2017-08-25 | 2020-03-05 | Ovid Therapeutics Inc. | Recombinant adeno-associated vectors |
| US20190076409A1 (en) | 2017-09-12 | 2019-03-14 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of narcolepsy |
| CN107595850A (zh) | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种有效提高睡眠质量的药物组合物及其用途 |
| KR20210039324A (ko) | 2018-04-06 | 2021-04-09 | 오비드 테라퓨틱스 인크. | 물질 사용 장애들의 치료에서 가복사돌의 사용 |
| EP3883566A4 (en) * | 2018-11-21 | 2022-09-07 | Certego Therapeutics Inc. | GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF |
-
2019
- 2019-11-21 EP EP19886329.2A patent/EP3883566A4/en active Pending
- 2019-11-21 SG SG11202105358RA patent/SG11202105358RA/en unknown
- 2019-11-21 US US17/295,845 patent/US20220008398A1/en active Pending
- 2019-11-21 GB GB2108720.0A patent/GB2594616A/en not_active Withdrawn
- 2019-11-21 CN CN201980089656.6A patent/CN113395962A/zh active Pending
- 2019-11-21 BR BR112021009944-1A patent/BR112021009944A2/pt unknown
- 2019-11-21 CA CA3120856A patent/CA3120856A1/en active Pending
- 2019-11-21 AU AU2019384157A patent/AU2019384157A1/en active Pending
- 2019-11-21 WO PCT/US2019/062554 patent/WO2020106927A1/en unknown
- 2019-11-21 MX MX2021005992A patent/MX2021005992A/es unknown
- 2019-11-21 US US16/691,049 patent/US11123332B2/en active Active
- 2019-11-21 JP JP2021529111A patent/JP2022514194A/ja active Pending
- 2019-11-21 KR KR1020217019089A patent/KR20210110585A/ko unknown
-
2021
- 2021-04-02 US US17/221,178 patent/US20220054461A1/en active Pending
- 2021-05-20 IL IL283311A patent/IL283311A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60021266T2 (de) | Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin | |
| US20070254858A1 (en) | Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects | |
| US20150119417A1 (en) | Methods for treating visceral fat conditions | |
| US20210030665A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| GB2594616A (en) | Gaboxadol for reducing risk of suicide and rapid relief of depression | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| EP2969001A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| Kuna et al. | Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma | |
| JPWO2020106927A5 (ko) | ||
| AU2010220830A1 (en) | Medicinal cosmetic lipoatrophy | |
| Vandewalker et al. | Addition of terbutaline to optimal theophylline therapy: Double blind crossover study in asthmatic patients | |
| Fujishima et al. | Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis | |
| WO2018051355A1 (en) | Tamoxifen or tamoxifen in combination with arginine/citrulline for the use in the treatment of muscular dystrophy | |
| Milligan et al. | A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. | |
| EP1032402A1 (en) | Citicoline to treat motor neuron diseases and demyelinating diseases | |
| JP2008513430A (ja) | 月経前症候群および月経前不快気分障害の処置のためのピンドロール | |
| US20160310510A1 (en) | Medicinal cosmetic lipoatrophy | |
| US20020198172A1 (en) | Method of treating motor neuron diseases and demyelinating diseases with citicoline | |
| US20240058308A1 (en) | Treatment and prevention of dry macular degeneration | |
| US20230149392A1 (en) | Treatment of major depressive disorder | |
| EP1448184B1 (en) | Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease | |
| WO2023026247A1 (en) | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea | |
| Yogaratnam et al. | Drugs that act on the respiratory tract | |
| CN106659710A (zh) | 用于治疗多发性硬化的方法 |